Navinci Diagnostics in a SEK 90 million Series A round, led by Segulah Medical, joined by Landegren Gene Technology AB, Nexttobe and Beijer Ventures

Round investors: Beijer Ventures AB nxt2b - Nexttobe AB Segulah Ulf Landegren